Author + information
- Woong Gil Choi1,
- Seung-Woon Rha2,
- Byoung Geol Choi2,
- Se Yeon Choi2,
- Sang-Ho Park3,
- Ji Young Park4,
- Yun-Hyeong Cho5,
- Won-Yu Kang6 and
- Dong Joo Oh2
Peripheral arterial disease (PAD) is an important predictor of adverse clinical outcomes following coronary revascularization. Patients with PAD have been found to have higher rates of adverse outcomes and poorer survival compared with patients without PAD. However, there have been limited data for long term clinical outcomes in patients with PAD undergoing percutaneous coronary intervention (PCI) in drug eluting stent (DES) era.
The study population consisted of 2903 consecutive patients underwent PCI from April 2007 to November 2010. Two-year cumulative major clinical outcomes of patients with PAD (n=101) were compared with patients without PAD (n=2802).
Baseline characteristics were balanced except patients with PAD were older (66.76 ± 10.1 vs. 62.90 ± 11.3 years, p = 0.020), had more diabetes (61.8 vs. 27.6 %, p = 0.002) and had longer total lesion length (50.38 ± 47.14 mm vs. 41.24 ± 39.93 mm, p = 0.005). Patients with PAD showed a strong trend toward higher rate of total mortality (13.6 vs. 6.3%, p = 0.051) despite of successful PCI results, but there was no significant difference in the incidence of cardiac death, target lesion revascularization (TLR), target vessel revascularization (TVR) and major adverse cardiac events (MACE, Table).
In our study, patients with PAD were associated with higher trend of increased total mortality up to 2 years as compared with those without PAD group following successful PCI, suggesting more special care should be exercised for this particular subset of patients.
|Variable, n (%)||Patient with PAD (n=101 pts)||Patients without PAD (n=2802pts)||P value|
|Total mortality||6 (13.6)||122 (6.3)||0.051|
|Cardiac death||3 (6.8)||78 (4.0)||0.356|
|Myocardial infarction||0 (0)||31 (1.6)||0.398|
|TLR||5 (11.4)||156 (8.1)||0.428|
|TVR||10 (22.7)||310 (16)||0.232|
|Total MACE||10 (22.7)||376 (19.4)||0.585|
TLR, TVR; target lesion and vessel revascularization
MACE; major adverse cardiac events